Ardelyx Target of Unusually High Options Trading (NASDAQ:ARDX)

Ardelyx, Inc. (NASDAQ:ARDX) saw unusually large options trading on Thursday. Stock traders purchased 7,048 call options on the stock. This is an increase of approximately 267% compared to the average daily volume of 1,919 call options.

Ardelyx Trading Up 8.7%

Shares of ARDX stock opened at $6.88 on Friday. The stock has a 50-day simple moving average of $6.02 and a 200 day simple moving average of $6.14. Ardelyx has a fifty-two week low of $3.21 and a fifty-two week high of $8.40. The stock has a market capitalization of $1.69 billion, a P/E ratio of -27.52 and a beta of 0.66. The company has a quick ratio of 4.11, a current ratio of 4.31 and a debt-to-equity ratio of 1.21.

Ardelyx (NASDAQ:ARDX) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Ardelyx had a negative net margin of 13.58% and a negative return on equity of 37.80%. The firm had revenue of $94.47 million for the quarter, compared to the consensus estimate of $92.78 million. During the same period in the prior year, the business earned ($0.17) EPS. The company’s quarterly revenue was up 27.5% compared to the same quarter last year.

Analyst Upgrades and Downgrades

ARDX has been the subject of several recent analyst reports. Piper Sandler raised Ardelyx from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $10.00 to $16.00 in a research note on Thursday, January 8th. Citigroup raised their target price on Ardelyx from $11.00 to $14.00 and gave the company a “buy” rating in a research note on Friday, January 9th. Wedbush reaffirmed an “outperform” rating and set a $19.00 target price on shares of Ardelyx in a research note on Monday, February 23rd. BTIG Research reaffirmed a “buy” rating and set a $17.00 target price on shares of Ardelyx in a research note on Friday, February 20th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ardelyx in a research note on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $15.70.

Insider Buying and Selling

In other news, insider Mike Kelliher sold 9,595 shares of the stock in a transaction on Friday, February 20th. The stock was sold at an average price of $5.85, for a total value of $56,130.75. Following the completion of the transaction, the insider owned 364,666 shares of the company’s stock, valued at approximately $2,133,296.10. This represents a 2.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Laura A. Williams sold 8,176 shares of the stock in a transaction on Friday, February 20th. The stock was sold at an average price of $5.85, for a total value of $47,829.60. Following the completion of the transaction, the insider directly owned 436,082 shares of the company’s stock, valued at approximately $2,551,079.70. The trade was a 1.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 128,604 shares of company stock valued at $751,917. Company insiders own 4.80% of the company’s stock.

Hedge Funds Weigh In On Ardelyx

Hedge funds and other institutional investors have recently modified their holdings of the stock. First Horizon Corp boosted its position in shares of Ardelyx by 120.4% in the 4th quarter. First Horizon Corp now owns 7,906 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 4,319 shares during the period. SBI Securities Co. Ltd. boosted its position in shares of Ardelyx by 147.0% in the 3rd quarter. SBI Securities Co. Ltd. now owns 10,253 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 6,102 shares during the period. Swiss Life Asset Management Ltd acquired a new position in shares of Ardelyx in the 3rd quarter valued at $57,000. Sumitomo Mitsui Trust Group Inc. acquired a new position in shares of Ardelyx in the 4th quarter valued at $60,000. Finally, State of Wyoming acquired a new position in shares of Ardelyx in the 2nd quarter valued at $61,000. Institutional investors and hedge funds own 58.92% of the company’s stock.

More Ardelyx News

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Q1 product and revenue strength: Ardelyx reported Q1 total product revenue of about $93.4M and overall revenue that beat estimates, driven by strong demand for IBSRELA which grew ~58% year?over?year to $70.1M — a key driver of the upside. Ardelyx Reports First-Quarter 2026 Financial Results
• Positive Sentiment: Company reiterated full?year revenue guidance of $410–$430M and reported a solid cash balance (~$238.1M), which supports ongoing commercialization and strategic investments. Press Release
• Positive Sentiment: Unusual options activity: buyers acquired ~7,048 call options (?+267% vs. typical), signaling speculative/structured bullish positioning into or after the print — this can amplify intraday upside. (trade report)
• Neutral Sentiment: Earnings call and management commentary emphasized continued commercial investment and pipeline progress; read the call highlights for detail on strategy and priorities. Earnings Call Highlights
• Neutral Sentiment: Full Q1 earnings call transcript is available for investors who want granular color on sales trends, patient starts, and SG&A/R&D pacing. Earnings Call Transcript
• Negative Sentiment: EPS miss: Ardelyx reported a GAAP loss of $0.15/share versus consensus loss of $0.13 (miss of $0.02); company remains unprofitable with negative net margin and return on equity metrics that could restrain some valuation upside. Zacks: Q1 loss, revenue beat

Ardelyx Company Profile

Ardelyx, Inc (NASDAQ: ARDX) is a clinical?stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio?renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.